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Introduction {#sec1}
============

Hydrogen sulfide (H~2~S) affects numerous aspects of animal physiology ([@bib67]), including long-term potentiation in the nervous system ([@bib1]), vasorelaxation ([@bib77]), oxygen sensing ([@bib52]), angiogenesis in the cardiovascular system ([@bib13], [@bib54]), and insulin secretion from endocrine cells in the pancreas ([@bib70]). While H~2~S at high concentrations is toxic, low levels impart numerous benefits including resistance to hypoxia ([@bib9]), neuroprotection ([@bib36]), protection from myocardial ischemia reperfusion injury ([@bib7], [@bib21]), modulation of inflammation ([@bib75]), and extension of longevity ([@bib47]). H~2~S is also produced endogenously by several enzymes, including 3-MST and the transsulfuration pathway (TSP) enzymes cystathionine β-lyase (CBS) and cystathionine γ-lyase (CGL) ([@bib33]). Mice lacking functional TSP activity are hypertensive ([@bib71]), display reduced angiogenic potential ([@bib63]), and are susceptible to aging-related neurodegeneration and osteoporosis ([@bib45], [@bib55]). Despite the implications for its pleiotropic beneficial effects, little is known about the systemic regulation of endogenous H~2~S production.

Previously, we reported that dietary restriction (DR), best known for increasing lifespan, stress resistance, and metabolic fitness in organisms across evolutionary boundaries, works partially through increasing endogenous H~2~S production ([@bib31]). In rodents, DR-mediated protection from hepatic ischemia reperfusion injury requires H~2~S generation by CGL, which is subject to regulation by sulfur amino acid intake ([@bib31], [@bib51], [@bib60]). Downstream mechanisms of H~2~S action in this context, and whether these are specific to DR or shared with other anti-aging interventions, remain unknown.

Like DR, reduced hypothalamic-pituitary axis activity is associated with resistance to age-related diseases, extended longevity, and improved metabolic fitness in rodents and humans. Long-lived rodent strains include hypopituitary Snell and Ames dwarf mice that lack growth hormone (GH) and thyroid-stimulating hormone (TSH) ([@bib5]). Specific ablation of the GH receptor (GHR) in GHR knockout mice (GHRKO) also increases lifespan, suggesting the specificity of the GH pathway in aging ([@bib15]). However, TH levels are also reduced in GHRKO mice, complicating the functional dissection of GH and TH activity in longevity control in vivo ([@bib30]). Subclinical hypothyroidism is associated with longevity in human centenarian studies ([@bib4], [@bib57]), and inactivating mutations in GHR are associated with metabolic fitness and reduced cancer incidence in humans ([@bib28]).

GHRKO mice are recalcitrant to further increase in lifespan or insulin sensitivity upon DR, consistent with at least partially overlapping mechanisms of action ([@bib10]). One such candidate mechanism is the insulin-like growth factor-1 (IGF-1) pathway, which is reduced upon DR as well as in hypopituitary/GHRKO longevity models. Here, we tested the hypothesis that increased H~2~S production is a shared phenotype in genetic models of longevity involving decreased GH/TH signaling with the potential to contribute to metabolic benefits. We found that GH and TH negatively regulate hepatic H~2~S production through distinct mechanisms, with functional consequences on feedback control of hepatic IGF-1 and TH production.

Results {#sec2}
=======

Increased Hepatic H~2~S Production in Long-Lived Hypopituitary Dwarf Mice In Vivo {#sec2.1}
---------------------------------------------------------------------------------

We examined the impact of reduced GH and TSH signaling on hepatic CGL and CBS mRNA and protein expression and H~2~S production capacity in Snell dwarf mice lacking these hormones ([Figures 1](#fig1){ref-type="fig"}A--1D). Male and female Snell dwarf mice had increases in hepatic CGL mRNA ([Figure 1](#fig1){ref-type="fig"}A) and protein (upper band) compared with wild-type (WT) littermates ([Figure 1](#fig1){ref-type="fig"}B). Hepatic CBS mRNA was not increased in either male or female mice ([Figure 1](#fig1){ref-type="fig"}A), but CBS protein levels were increased in male mice compared with WT littermates ([Figure 1](#fig1){ref-type="fig"}B). Consistent with enzyme levels, H~2~S production capacity, as measured by the lead sulfide method, was increased in liver homogenates in both male and female Snell dwarf mice ([Figure 1](#fig1){ref-type="fig"}C). Importantly, endogenous H~2~S levels, as detected by two-photon microscopy using the H~2~S-specific chemo-fluorescent probe P3 ([@bib62]), were also increased in Snell dwarf livers ([Figure 1](#fig1){ref-type="fig"}D).Figure 1Increased Hepatic H~2~S Production in Long-Lived Hypopituitary Dwarf Mice In Vivo(A--D) Hepatic CGL and CBS mRNA expression (n = 3/group) (A), protein expression (n = 3/group) (B), H~2~S production capacity via the lead sulfide method (n = 3/group) (C), and endogenous H~2~S production via two-photon florescence microscopy (n = 3/group) (D) in male and female WT or Snell dwarf mice as indicated. Scale bar, 25 μm. Asterisk indicates the significance of the difference between genotypes within sex; ^∗^p \< 0.05.(E) Liver H~2~S production capacity in 18-month-old female Ames dwarf or WT mice treated +/− growth hormone during postnatal development at weeks 2-8 (n = 9--14/group). The asterisk indicates the significance of the difference between the WT+Saline control group and experimental group, and the \# sign indicates the significance of the difference between +Saline and +GH; ^∗^/^\#^p \< 0.05.(F) Liver H~2~S production capacity in mice treated with saline control or lanreotide (n = 4/group). The asterisks indicate the significance of the difference between treatment groups; ^∗^p \< 0.05. Error bars are ± SEM. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

To test if increased H~2~S production could have functional consequences on hypopituitary dwarf mice, we made use of the fact that GH treatment of Ames dwarf mice during early post-natal development (weeks 2-8) reverses lifespan and metabolic effects ([@bib53]). Early GH treatment normalized (reduced) hepatic H~2~S production capacity ([Figure 1](#fig1){ref-type="fig"}E) and CGL protein levels ([Figure S1](#mmc1){ref-type="supplementary-material"}A) measured later in life at 18 months of age. These data demonstrate a correlation between hepatic H~2~S production capacity and longevity in the Ames dwarf model.

Because Snell and Ames dwarf mice lack GH and TH signals from birth, we next tested the plasticity of H~2~S regulation by GH/TH in WT adult mice by pharmacological inhibition with the somatostatin analog, lanreotide ([@bib38]). Treatment for 8 days increased liver H~2~S production capacity ([Figure 1](#fig1){ref-type="fig"}F) and CGL protein levels ([Figure S1](#mmc1){ref-type="supplementary-material"}B) without affecting body weight ([Figure S1](#mmc1){ref-type="supplementary-material"}C) or food intake ([Figure S1](#mmc1){ref-type="supplementary-material"}D). These data demonstrate that GH and TSH deficiency/inhibition promote hepatic H~2~S production in vivo.

GH Signaling Inhibits Hepatic H~2~S Production In Vivo {#sec2.2}
------------------------------------------------------

We next focused specifically on the potential of GH to regulate H~2~S production using global GHRKO mice. Male and female GHRKO mice had increases in hepatic CGL mRNA and protein relative to WT littermates ([Figures 2](#fig2){ref-type="fig"}A and 2B). As in Snell dwarf mice, CBS protein was increased in GHRKO males, while CBS mRNA expression was unchanged ([Figures 2](#fig2){ref-type="fig"}A and 2B). Hepatic H~2~S production capacity was increased in both male and female GHRKO mice compared with WT littermates ([Figure 2](#fig2){ref-type="fig"}C). Thus, the lack of GH signaling due to global deletion of its receptor results in increased hepatic H~2~S production capacity in vivo.Figure 2Growth Hormone Signaling Inhibits Hepatic H~2~S Production In vivo(A--C) Hepatic CGL and CBS mRNA expression (n = 3/group) (A), protein expression (n = 3/group) (B), and H~2~S production capacity (n = 3/group) (C) in male and female growth hormone receptor knockout (GHRKO) mice. The asterisk indicates the significance of the difference between genotypes within sex; ^∗^p \< 0.05.(D) Liver H~2~S production capacity (n = 8/group) in WT mice treated for 2 weeks with recombinant IGF-1, GH, or saline vehicle as indicated. The asterisk indicates the significance of the difference between GH and saline treatment; ^∗^p \< 0.05.(E and F) Liver H~2~S production capacity in male and female IRS-1 WT or KO mice (n = 4--11/group) (E) and in male FGF21 WT or overexpressing (OE) mice (n = 6/group) (F). The asterisk indicates the significance of the difference between genotypes within sex; ^∗^p \< 0.05. Error bars are ± SEM. See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

As IGF-1 is a major downstream effector of hepatic GH signaling, we tested the effects of 2 weeks of recombinant human IGF-1 or human GH injections on hepatic H~2~S production capacity and CGL protein expression. While IGF-1 had no effect relative to mock treatment, GH injection reduced hepatic H~2~S production capacity ([Figure 2](#fig2){ref-type="fig"}D) and hepatic CGL protein expression ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Consistent with GH-mediated repression of H~2~S production capacity, GH injection suppresses CGL mRNA expression according to independent data obtained from NCBI GeoProfile GDS862/8.2.2.10/Cth ([@bib2]) ([Figure S2](#mmc1){ref-type="supplementary-material"}B). Together, these data indicate that GH and GHR signaling suppress hepatic H~2~S production capacity in vivo independent of IGF-1.

To confirm the specific role of GHR signaling in H~2~S regulation, we tested the potential of two intracellular mediators of hepatic GHR signaling, IRS-1 and FGF21, to alter H~2~S production. IRS-1 is an adaptor protein involved in both insulin and GHR signaling ([@bib43]), and global IRS-1KO mice are long lived ([@bib59]). IRS-1KO mice had increased hepatic H~2~S production capacity ([Figure 2](#fig2){ref-type="fig"}E) and elevated CGL protein expression ([Figure S2](#mmc1){ref-type="supplementary-material"}C). Because IRS-1KO mice are insulin resistant ([@bib8]), we tested the potential contribution of insulin receptor (IR) signaling using liver-specific insulin receptor knockout (LIRKO mice). However, LIRKO mice displayed decreased hepatic H~2~S production capacity ([Figure S2](#mmc1){ref-type="supplementary-material"}D), consistent with GH signaling rather than IR signaling in negative regulation of hepatic H~2~S production. In addition, long-lived mice overexpressing the fasting hormone FGF21 ([@bib76]), an intracellular inhibitor of GH signaling ([@bib32]), displayed increased hepatic H~2~S production capacity ([Figure 2](#fig2){ref-type="fig"}F) and CGL protein ([Figure 2](#fig2){ref-type="fig"}E). These data are consistent with GH/GHR as a negative regulator of H~2~S production capacity, and show a positive correlation between increased hepatic H~2~S production capacity and extended longevity in vivo.

GH/GHR Signaling Inhibits Hepatic H~2~S Production In Vitro {#sec2.3}
-----------------------------------------------------------

To elucidate how GHR signaling controls H~2~S production, we turned to overnight serum withdrawal with or without added recombinant GH in cell culture as a cell-autonomous model. Endogenous H~2~S production was measured using the fluorescent P3 probe and visualized/quantitated by two-photon microscopy or UV spectrophotometry. We first established the ability of overnight serum withdrawal to induce robust endogenous H~2~S production, and the specific contribution of TSP enzymes CGL and CBS to this process using WT versus CGLKO fibroblasts with or without PAG and AOAA, inhibitors of CGL and CBS, respectively ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B). Interestingly, while CGL is the predominant H~2~S producer in liver in vivo ([@bib33]), and responsible for the increase in H~2~S production capacity in response to DR ([@bib31]), CBS also contributed to the increase in H~2~S production upon serum withdrawal in primary fibroblasts in vitro ([Figure S3](#mmc1){ref-type="supplementary-material"}A).

In cultured mouse primary hepatocytes, H~2~S production was also significantly increased upon serum deprivation ([Figures 3](#fig3){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}C). Importantly, addition of recombinant GH at the level required to induce robust phosphorylation of Stat5 (p-Stat5), and transcription of *Igf-1* ([Figure S3](#mmc1){ref-type="supplementary-material"}D--S3F), dampened the increase in H~2~S production induced by serum deprivation ([Figures 3](#fig3){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}C).

Canonical GH-induced intracellular signaling begins with its binding to and dimerization of the GHR on the plasma membrane, leading to stimulation of numerous signaling cascades, including Jak2/Stat5, followed by the transcriptional/translational regulation of target genes such as *Igf-1*. While addition of GH into medium containing serum did not change H~2~S production, blocking GH signaling with the Jak2 inhibitor AZD1480 ([@bib27]) moderately increased endogenous H~2~S in hepatocytes cultured in Complete medium with additional GH ([Figures 3](#fig3){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}G). Furthermore, the increase in H~2~S production induced by serum deprivation and blocked by GH was fully restored with addition of AZD1480 ([Figures 3](#fig3){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}G). Exogenous FGF21 increased H~2~S production despite the presence of full serum ([Figures 3](#fig3){ref-type="fig"}C and [S3](#mmc1){ref-type="supplementary-material"}H). Together, these data suggest that GH acts through the Jak2/Stat5 pathway to repress H~2~S production in cells.

Because of increased TSP mRNA/protein expression in Snell/Ames and GHRKO livers in vivo, we next asked if GH regulates hepatic H~2~S production in a cell-autonomous manner via transcriptional control of TSP gene expression, in a manner similar to control of Igf-1 ([Figure 3](#fig3){ref-type="fig"}D). Surprisingly, serum withdrawal from primary hepatocytes failed to increase CGL mRNA or protein to the same levels as observed in vivo ([Figures S3](#mmc1){ref-type="supplementary-material"}I and S3J). Similarly, pharmacological inhibition of GH/GHR action with AZD1480 or FGF21 failed to significantly affect TSP gene expression as they did IGF-1 expression ([Figure 3](#fig3){ref-type="fig"}D). Together, these data suggest that neither transcriptional nor translational control of CBS or CGL are the major mechanisms of hepatic H~2~S regulation by GH in cells.Figure 3Growth Hormone Receptor Signaling Inhibits Hepatic H~2~S Production In Vitro(A--C) Endogenous H~2~S production in primary mouse hepatocytes as measured via two-photon fluorescent microscopy under different medium conditions: (A) +/−growth serum and +/−GH, with the asterisk indicating the significance of the difference between Complete and −Serum, and the \# sign indicating the significance of the difference between −Serum and −Serum+GH, ^∗/\#^p \< 0.05; (B) +/−growth serum, +/−GH, +/−AZD1480, with the asterisk indicating the significance of the difference between Complete and −Serum in each group, and the \# sign indicating the significance of the difference between −Serum (−) (no addition) and −Serum+ZD1480; and the \$ sign indicating the significance of the difference between +GH and +GH+ZD1480 for both Complete and −Serum conditions, ^∗/\#/\$^p \< 0.05; (C) +/−FGF21 in Complete medium containing serum, with the asterisk indicating the significance of the difference between Complete and Complete+FGF21; ^∗^p \< 0.05.(D) mRNA expression of *Igf-I*, Cgl, and Cbs in mouse primary hepatocytes. The asterisk indicates the significance of the difference between +GH and +GH+ZD1480; ^∗^p \< 0.05.(E and F) Endogenous H~2~S production in mouse primary hepatocytes by florescent microscopy after overnight treatment under the indicated medium conditions followed by addition of the P3 probe for 1 hr. The asterisk indicates the significance of the difference between Complete and −Serum, and the \# sign indicates the significance of the difference between −Serum and −Serum+BAF (E), or −Serum−SAA and −Serum−SAA+CQ (F); ^∗\#^p \< 0.05.(G and H) Endogenous H~2~S production in Hepa1-6 cells with or without knockdown of autophagy components ATG5 and ATG7 by shRNA (G) or in MEFs by genetic knockout of ATG5 and ATG7 (H) detected by UV spectrophotometry after overnight treatment with or without serum followed by addition of the P3 probe for 1 hr. The asterisk indicates the significance of the difference between Complete and −Serum in the Control group, and the \# sign indicates the significance of the difference between −Serum Control and −Serum ATG5 deficient or −Serum ATG7 deficient; ^∗/\#^p \< 0.05. Each experiment was repeated at least three times. Scale bars, 100 μm (A--C, E, and F). Error bars are ± SEM. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

Regulation of endogenous H~2~S production via CBS and CGL in cells could instead occur post-translationally or be driven by substrate availability ([@bib33], [@bib46], [@bib79]). While the endogenous source of free cysteine for H~2~S production is currently unknown, cellular autophagy is increased in long-lived dwarf mice ([@bib68]), thus potentially fueling the increase in H~2~S production observed upon GH signaling inhibition. Consistent with this notion, pharmacological inhibition of autophagy with bafilomycin (BAF) or chloroquine (CQ) blocked H~2~S production induced by serum removal ([Figures 3](#fig3){ref-type="fig"}E, 3F, [S3](#mmc1){ref-type="supplementary-material"}K, and S3L), even in the presence of media lacking sulfur amino acids (SAA) ([Figure 3](#fig3){ref-type="fig"}F). Similarly, inhibition of autophagy by genetic knockdown ([Figures 3](#fig3){ref-type="fig"}G, [S3](#mmc1){ref-type="supplementary-material"}M) or knockout ([Figure 3](#fig3){ref-type="fig"}H and [S3](#mmc1){ref-type="supplementary-material"}N) of Autophagy Protein 5 (ATG5) or 7 (ATG7) decreased H~2~S production upon serum withdrawal. Taken together, these data suggest that GH is a negative regulator of H~2~S production in vitro through autophagy-dependent substrate-level and/or enzymatic activity control rather than transcriptional control of CGL and CBS expression.

Hypothyroidism Increases Hepatic H~2~S Production In Vivo {#sec2.4}
---------------------------------------------------------

We next considered the potential of TH to explain the transcriptional control of hepatic CGL expression observed in these models in vivo but not readily attributable to GHR activity in vitro. Adult male mice were made hypo-, eu-, or hyperthyroid by inhibiting endogenous thyroid function with a PTU-containing low iodine diet (PTU/LID) with or without TH supplementation (in the form of T~3~). To validate the system, we confirmed that known TH target genes were regulated as expected in the hypothyroid (PTU/LID), euthyroid (PTU/LID + low dose T3), and hyperthyroid (PTU/LID + high dose T~3~) states ([Figure S4](#mmc1){ref-type="supplementary-material"}A).

Circulating T~3~ levels strongly correlated with expression of genes in the methionine cycle and TSP including CGL, which was activated in the hypothyroid state and strongly repressed by increasing doses of T~3~ ([Figure 4](#fig4){ref-type="fig"}A). A similar correlation was observed between T~3~ and hepatic protein levels of CGL and CBS ([Figure 4](#fig4){ref-type="fig"}B) as well as hepatic H~2~S production capacity ([Figures 4](#fig4){ref-type="fig"}C and [S4](#mmc1){ref-type="supplementary-material"}B). Metabolomics revealed broader effects of circulating T~3~ on hepatic methionine cycle and TSP metabolites, including regulation of homocysteine, cystathionine, and cysteine ([Figure 4](#fig4){ref-type="fig"}D). Finally, we confirmed that T~3~ alone, without the induction of hypothyroidism via a PTU/LID, reduced hepatic CGL and CBS mRNA ([Figure 4](#fig4){ref-type="fig"}E), correlating with protein levels ([Figure 4](#fig4){ref-type="fig"}F), hepatic H~2~S production capacity ([Figure 4](#fig4){ref-type="fig"}G) and characteristic changes in hepatic metabolites, including cystathionine and cysteine ([Figure S4](#mmc1){ref-type="supplementary-material"}C).Figure 4Hypothyroidism Increases and Thyroid Hormone Represses Hepatic H~2~S Production In Vivo(A--D) mRNA expression (n = 4) (A), protein expression (n = 3) (B), H~2~S production capacity (n = 4) (C), and transmethylation/transsulfuration metabolite levels by liquid chromatography-tandem mass spectrometry (n = 4) (D) in livers of mice under hypo- (PTU+Saline), hyper- (PTU+high dose T3), and eu-(PTU+low dose T3) thyroid states. The asterisks indicate the significance of the difference from the hypothyroid state (PTU+Saline); ^∗^p \< 0.05.(E--G) Analysis of TH-responsive and sulfur amino acid metabolism-associated mRNA levels (n = 4--6) (E), protein expression (n = 5) (F), and H~2~S production capacity (n = 5) (G) in livers of mice treated with T3 (hyperthyroid) versus vehicle (saline) control (euthyroid). The asterisk indicates the significance of the difference between vehicle and +T3 groups; ^∗^p \< 0.05. Error bars are ± SEM. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

Thyroid Hormone Signaling through TRβ Suppresses Hepatic H~2~S Production {#sec2.5}
-------------------------------------------------------------------------

While T~3~ acts broadly in vivo through multiple TH receptors, its action in liver depends primarily on TH receptor β1 (TRβ1). To test if negative regulation of TSP expression and H~2~S production capacity by T~3~ is organ autonomous or the result of systemic T~3~ action, we took advantage of the T~3~ analog GC-1, which preferentially acts on the liver via its uptake and specificity for TRβ1. GC-1 predictably modulated known T~3~ target genes in the liver ([Figure 5](#fig5){ref-type="fig"}A, left) and negatively regulated components of the hepatic methionine cycle and TSP, including CGL and CBS gene and protein expression ([Figures 5](#fig5){ref-type="fig"}A and 5B). GC-1 also reduced hepatic H~2~S production capacity ([Figure 5](#fig5){ref-type="fig"}C) and altered hepatic TSP metabolites, including cystathionine, similar to T~3~ ([Figure S5](#mmc1){ref-type="supplementary-material"}A).Figure 5Thyroid Hormone Signaling through TRβ Represses Hepatic H~2~S Production In Vivo(A--C) Analysis of TH-responsive and sulfur amino acid metabolism-associated mRNA levels (n = 4--6) (A), protein expression (n = 6) (B), and H~2~S production capacity (n = 5) (C) in livers of mice treated with GC-1 versus vehicle (saline) control. The asterisk indicates the significance of the difference between vehicle (saline) control (euthyroid) and +GC-1 groups (hyperthyroid); ^∗^p \< 0.05.(D and E) Liver CBS and CGL protein expression (D) and H~2~S production capacity (E) in mice with indicated TRβ status (WT, homozygous WT; TRβ^PV/+^, Het; TRβ^PV/PV^, homozygous mutant; n = 4--5/group). The asterisk indicates the significance of the difference between WT and TRβ^PV/PV^, and the \# sign indicates the significance of the difference between TRβ^PV/+^ and TRβ^PV/PV^; ^∗/\#^p \< 0.05.(F) Fold enrichment of TRβ binding to genetic regulator elements in sulfur amino acid metabolism and H~2~S producing genes in the livers of mice infected with Ad-GFP (control) or Ad-TRβ while on PTU diets +/−T3 injection as indicated (n = 5/group). The asterisk indicates the significance of the difference between the Ad-GFP PTU and Ad-TRβ PTU or Ad-TRβ T3 groups, and the \# sign indicates the significance of the difference between the Ad-TRβ PTU and Ad-TRβ T3 groups; ^∗/\#^p \< 0.05.(G and H) Liver ATF4 protein expression in mice due to PTU/T3 administration (G) (n = 4/group) or TRβ mutations (H) (n = 4--5/group). The asterisks indicate the significance of the difference between Hyper-T and Eu-T or Hypo-T (G), or WT and TRβ^PV/+^ or TRβ^PV/PV^ (H), and the \# sign indicates the significance of the difference between TRβ^PV/+^ and TRβ^PV/PV^ (H), ^∗/\#^p \< 0.05. Error bars are ± SEM. See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

The genetic requirement for TRβ1 in repression of hepatic TSP expression and H~2~S production was tested in mice with a mutant and defective TRβ1 isoform (TRβ^PV/PV^) ([@bib78]). TRβ^PV/PV^ mice had higher CGL and CBS protein levels in the liver and enhanced H~2~S production capacity than heterozygote or WT control animals ([Figures 5](#fig5){ref-type="fig"}D and 5E). Interestingly, neither CGL nor CBS mRNA levels were significantly altered in the TRβ^PV/PV^ mice compared with controls ([Figure S5](#mmc1){ref-type="supplementary-material"}B), possibly due to long-term upregulation of this pathway in these animals. Thus, an intact TRβ regulates H~2~S production, but it also remains possible that TRα plays a role in TRβ^PV/PV^ mutants.

Finally, to test the hypothesis that TRβ1 regulates H~2~S production capacity by direct transcriptional control of TSP genes in vivo, we examined the TRβ cistrome that we generated previously ([@bib56]) for binding sites within regulatory regions of the CBS and CGL genes. Chromatin immunoprecipitation analysis revealed enrichment of TRβ binding at several loci on the CBS and CGL genes, as well as other genes of the methionine cycle ([Figure 5](#fig5){ref-type="fig"}F). Interestingly, T~3~ injection resulted in a significant reduction in occupancy of TRβ on CGL and Bhmt promoters/enhancers, but not CBS binding sites. While the detailed mechanisms of negative regulation of hepatic TSP gene expression by T~3~ and TRβ1 remain to be elucidated, these data suggest regulation of hepatic H~2~S production via TRβ-dependent repression of TSP gene expression.

In addition to negative regulation by T~3~/TRβ as described here, CGL gene expression is positively regulated by the stress response transcription factor ATF4 in reaction to cysteine restriction on the cell-autonomous level ([@bib39], [@bib61]) and in livers of mouse models of DR and Snell dwarfism ([@bib42]). Surprisingly, we found that reduction of global TH signaling via a PTU/LID diet ([Figure 5](#fig5){ref-type="fig"}G), or liver-specific signaling in TRβ^PV/PV^ mice ([Figure 5](#fig5){ref-type="fig"}H), increased hepatic ATF4 protein levels. Despite the increase in hepatic ATF4 protein in Snell dwarf mice ([Figure S5](#mmc1){ref-type="supplementary-material"}C), we were not able to detect significantly elevated levels in GHRKO mice ([Figure S5](#mmc1){ref-type="supplementary-material"}D). Thus, hyperthyroidism is associated with negative regulation of CGL expression through direct binding and repression of the CGL locus by T~3~-bound TRβ1, while hypothyroidism is associated with increased CGL expression indirectly through derepression of the transcriptional activator ATF4, possibly by hypothyroidism-induced endoplasmic reticulum stress ([@bib80]).

Additive Suppression of Hepatic H~2~S Production by TH and GH In Vitro {#sec2.6}
----------------------------------------------------------------------

Having identified GH- and TH-dependent control of hepatic H~2~S production capacity, we next sought to determine the potential interaction between the two in a tractable in vitro system. Because primary murine hepatocytes do not respond well to T~3~, we employed a murine hepatic cell line, Hepa1-6, stably transfected with the TRβ isoform. Upon addition of T~3~ to this cell line, known T~3~ targets including gpd2 and bcl3 were induced, while methionine cycle genes mat1a and ahcy were repressed ([Figure 6](#fig6){ref-type="fig"}A). Importantly, both CGL and CBS were downregulated by T~3~ in these cells ([Figure 6](#fig6){ref-type="fig"}A), although only CGL was regulated in a similar fashion at the protein level ([Figure 6](#fig6){ref-type="fig"}B). Endogenous H~2~S production assessed using the P3 probe was reduced upon T~3~ addition, confirming its direct ability to regulate endogenous H~2~S through repression of CGL mRNA expression ([Figure 6](#fig6){ref-type="fig"}C).Figure 6Additive Suppression of Hepatic H~2~S Production by TH and GH In Vitro(A--C) mRNA levels (n = 3) (A), protein expression (n = 3) (B), and endogenous H~2~S production (n = 3) (C) in TH-responsive Hepa1-6 cells treated with T3 at the indicated concentration. The asterisk indicates the significance of the difference between vehicle control and T3 treatment and the hash indicates the significance of the difference between different T3 dosage groups; ^∗/\#^p \< 0.05.(D) Endogenous H~2~S production in TH-responsive Hepa1-6 cells grown in Complete medium or −Serum medium +/−GH +/−T3. The asterisk indicates the significance of the difference between Complete and −Serum within the GH/T3 treatment group, and the \# sign indicates the significance of the difference between "w/out Additions" and +GH, +T3, or +GH+T3 groups within the −Serum grouping; ^∗^/^\#^p \< 0.05. Scale bars, 100 μm (C and D). Error bars are ± SEM. See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

We next tested the individual and combined contributions of GH and TH in regulation of endogenous H~2~S production in this cell line. Overnight serum withdrawal resulted in a 2.5-fold increase in endogenous H~2~S levels ([Figure 6](#fig6){ref-type="fig"}D). Addition of GH or TH individually each resulted in a 50% decrease in H~2~S levels, while together they restored H~2~S to baseline levels seen in cells maintained in full serum ([Figure 6](#fig6){ref-type="fig"}D). Finally, gene expression analysis confirmed the effects of TH, but not GH, on TSP gene expression ([Figure S6](#mmc1){ref-type="supplementary-material"}). Taken together, GH and TH work additively to suppress hepatic H~2~S production in a cell-autonomous manner by distinct mechanisms.

CGL/H~2~S Required for Negative Regulation of TH and GH/IGF-1 Signaling {#sec2.7}
-----------------------------------------------------------------------

What are the functional consequences of increased H~2~S production in the context of reduced GH and/or TH signaling? We first approached this question by testing the genetic requirement for CGL in increased hepatic H~2~S production observed upon hypothyroidism. CGL protein and H~2~S production capacity were increased in hypothyroid WT mice on the PTU/LID diet compared with euthyroid WT mice on the normal diet, but were undetectable in littermate CGL KO mice on either diet ([Figures 7](#fig7){ref-type="fig"}A and 7B, and [Figure S7](#mmc1){ref-type="supplementary-material"}A). No differences in food intake ([Figure S7](#mmc1){ref-type="supplementary-material"}B), body weight ([Figure S7](#mmc1){ref-type="supplementary-material"}C), or protein levels of the other H~2~S-producting enzymes CBS and 3-MST ([Figures 7](#fig7){ref-type="fig"}A and [S7](#mmc1){ref-type="supplementary-material"}A) were observed between genotypes. We conclude that CGL is required for increased hepatic H~2~S production upon decreased TH signaling.Figure 7CGL/H~2~S Is Required for Negative Regulation of TH and GH/IGF-I Signaling(A and B) Western blot analysis of H~2~S-producing enzymes CGL, CBS, and 3MST (n = 3) (A) and H~2~S production capacity in livers of CGL WT and KO mice on Normal and PTU diets (n = 4--5) (B). The asterisk indicates the significance of the difference relative to CGL WT mice on the Normal diet; ^∗^p \< 0.05.(C) Serum T4 levels over a 3-week time course of Normal versus PTU diets in CGL WT and KO mice as indicated (n = 4--5).(D) Pituitary mRNA expression of TSHα and TSHβ in CGL WT and KO mice after 3 weeks of Normal or PTU diet (n = 4--5). The asterisk indicates the significance of difference between diets within genotype, and the \# sign indicates the significance of difference between CGL WT and CGL KO mice on the PTU diet; ^∗^/^\#^p \< 0.05.(E) Serum TSH levels after 3 weeks of Normal or PTU diet in CGL WT and KO mice (n = 4--5). The asterisk indicates the significance of difference between diets within genotype, and the \# sign indicates the significance of difference between CGL WT and CGL KO mice on the PTU diet; ^∗^/^\#^p \< 0.05.(F) Percent change in serum T4 levels after 3 days of fasting in CGL WT and CGL KO mice (n = 3--4). The asterisk indicates the significance of the difference between day 0 and day 3 T4 levels; ^∗^p \< 0.05.(G--I) Pituitary GH mRNA expression (n = 4--5) (G), liver GHR and IGF-I mRNA expression (n = 4--5) (H), and serum IGF-1 (n = 4--5) (I) in CGL WT and KO mice after 3 weeks on a Normal or PTU diet as indicated. The asterisk indicates the significance of the difference between diets within genotype, and the \# sign indicates the significance of the difference between genotypes on the PTU diet; ^∗/\#^p \< 0.05.(J) Fold change in serum IGF-I between day 0 and day 3 of a 3-day fast in CGL WT and KO mice (n = 3--4/group). The asterisk indicates the significance of the difference between day 3 and day 0; ^∗^p \< 0.05.(K) Serum IGF-1 levels in mice 7 days after adenoviral infection with Ad-Null control or Ad-CGL overexpression adenovirus expressed relative to Ad-Null control (n = 4/group). The asterisk indicates the significance of the difference between Ad-Null and Ad-CGL; ^∗^p \< 0.05.(L) Fold change in serum IGF-1 after a 2-day fast in female CGL WT and KO mice with +/−NaHS supplementation in the CGL KOs (n = 4--5/group). The asterisks indicate the significance of the difference between serum IGF-1 levels on day 2 compared with day 0; ^∗^p \< 0.05.(M) Relationship between diet, GH/TH, and H~2~S production.Error bars are ± SEM. See also [Figure S7](#mmc1){ref-type="supplementary-material"}.

Surprisingly, CGL KO mice failed to achieve the same degree of hypothyroidism as WT controls on the PTU/LID diet. This was first observed systemically upon measuring circulating T~4~, which remained elevated in CGL KO mice on the PTU/LID diet ([Figure 7](#fig7){ref-type="fig"}C), and was confirmed by TSHβ subunit gene expression in the pituitary ([Figure 7](#fig7){ref-type="fig"}D) and circulating TSH in the serum ([Figure 7](#fig7){ref-type="fig"}E), both of which failed to increase in CGL KO mice to WT levels on the PTU/LID diet.

These data suggest a functional role for CGL-derived H~2~S in systemic feedback control of TH signaling, possibly through modulation of circulating T~4~ levels. To test this further, CGL KO and WT mice were subject to fasting, a known suppressor of the hypothalamic-pituitary-thyroid axis on a more rapid timescale than the PTU/LID paradigm ([@bib66]). While serum T~4~ levels decreased in WT mice subject to a 3-day fast, T~4~ levels actually increased slightly upon fasting in CGL KO mice ([Figure 7](#fig7){ref-type="fig"}F), despite similar weight loss between genotypes ([Figure S7](#mmc1){ref-type="supplementary-material"}D). Taken together, these data suggest reciprocal negative regulation of H~2~S production by TRβ-dependent repression of hepatic CGL gene transcription, and T~4~ metabolism by CGL-derived H~2~S.

We next considered the potential role of CGL-derived H~2~S in negative regulation of global and hepatic GH action. In CGL KO mice, expression of pituitary GH mRNA ([Figure 7](#fig7){ref-type="fig"}G), hepatic GHR and IGF-1 mRNAs ([Figure 7](#fig7){ref-type="fig"}H), and circulating IGF-1 levels ([Figure 7](#fig7){ref-type="fig"}I) were inappropriately maintained and/or elevated upon PTU/LID relative to WT mice. Similar to its effects on circulating T~4~, fasting significantly decreased serum IGF-1 in WT mice, but not in CGL KO mice ([Figure 7](#fig7){ref-type="fig"}J).

Finally, we tested the sufficiency of CGL-derived H~2~S or chemical H~2~S donors to lower GH signaling independent of PTU/LID or fasting. One week after adenoviral-mediated CGL overexpression in WT mice, which resulted in increased liver H~2~S production capacity ([Figure S7](#mmc1){ref-type="supplementary-material"}E), serum IGF-1 levels were significantly reduced relative to the adenoviral null control ([Figure 7](#fig7){ref-type="fig"}K). In CGL KO mice subjected to a 2-day fast, intraperitoneal administration of NaHS rescued the expected drop in serum IGF-1 levels ([Figure 7](#fig7){ref-type="fig"}L) and serum T~4~ levels ([Figure S7](#mmc1){ref-type="supplementary-material"}F). In WT mice, NaHS was sufficient to reduce circulating IGF-1 levels after acute injection ([Figure S7](#mmc1){ref-type="supplementary-material"}G) or long-term treatment in the drinking water in combination with the slow-releasing H~2~S donor GYY4137 ([@bib40]) ([Figure S7](#mmc1){ref-type="supplementary-material"}H). These findings are consistent with a role for CGL-derived endogenous H~2~S in negative regulation of GH and TH signaling.

Discussion {#sec3}
==========

H~2~S as a Common Endpoint in Models of Longevity and Metabolic Homeostasis {#sec3.1}
---------------------------------------------------------------------------

Reduced GH/IGF-1 action and DR represent the most widely studied classes of anti-aging models in rodents, but mechanisms underlying pleiotropic benefits on lifespan, healthspan, and stress resistance in these models, and the relationship between them, remain unclear. Previously we found that increased endogenous H~2~S production upon DR is necessary and sufficient for surgical stress resistance in mice, and associated with extended longevity in fly, worm, and yeast models ([@bib31]). Here, we found that increased endogenous hepatic H~2~S production capacity was common to multiple long-lived mouse strains. As shown in the model in [Figure 7](#fig7){ref-type="fig"}M, GH and TH signaling were identified as negative regulators of hepatic H~2~S production. Unexpectedly, CGL was required for downregulation of T~4~ and IGF-1 in response to PTU/LID or fasting. Taken together, these data are consistent with increased hepatic H~2~S as a common denominator among DR and reduced GH/IGF-1-based pro-longevity models. Further, it points to negative regulation of TH and GH/IGF-1 signaling as a potential mechanism of H~2~S action in this context.

A limitation of this study lies in the quantitation of H~2~S levels. Much of the data was based on H~2~S production capacity using the lead acetate method, a measure of H~2~S production under conditions in which exogenous substrate (L-Cys) and co-factor (VitB6) are supplied in excess. While specific for H~2~S and sensitive for use in organ extracts with high production capacity, the more sensitive P3 fluorescent probe was required for measuring H~2~S production in individual cells in tissue culture or frozen liver sections. Importantly, the P3 probe reports on free H~2~S either generated de novo or released from sulfane sulfur without the addition of substrate or co-factor, thus making it possible to probe actual H~2~S production with endogenous substrates. While neither method is suited for absolute quantitation of H~2~S, both techniques showed increases in liver of Snell dwarf mice versus WT controls. Finally, while the importance of CGL-derived H~2~S was addressed by exogenous H~2~S supplementation in the context of CGL KO mice, our data in no way rule out potential contributions of other CGL-dependent metabolites such as glutathione.

Interactions between Nutrient Restriction, Endocrine Signaling, and H~2~S Production {#sec3.2}
------------------------------------------------------------------------------------

DR benefits overlap those of reduced GH/TH signaling, and indeed DR has been proposed to work, at least partially, the hypothalamic-pituitary axis, through modulation of somatotropic cells ([@bib11]). The ability of DR to further extend longevity or improve metabolic fitness is blunted in most, but not all ([@bib6]), hypopituitary or GHRKO mouse studies ([@bib3], [@bib10], [@bib12]). In addition, GH supplementation concurrent with DR reverses some DR-related metabolic effects ([@bib26]). Hormonally, DR alters hypothalamic activity ([@bib16]), lowers GH ([@bib24]) and TH secretion ([@bib23], [@bib48]), and reduces hepatic GHR expression ([@bib17]).

In addition to overlap between DR and reduced TH/GH signaling, genetic models of extended longevity associated with decreased GH/IGF-1 signaling also have decreased TH activity ([@bib25]). Conversely, reduction of TH signaling results in decreased GHR production and signaling ([@bib18]). Re-addition of these hormones into hypopituitary dwarf mice individually or in combination reverses many of the associated phenotypes ([@bib19], [@bib53]).

Despite these interconnections, here we found distinct, additive contributions of TH and GH to regulation of H~2~S production independent of diet. TH directly regulated CGL and CBS gene expression via TRβ acting as a transcriptional repressor, while GH via GHR controlled H~2~S production in an autophagy-dependent manner suggestive of substrate-level control. In addition, TH negatively regulated protein levels of the ATF4 transcription factor, a known direct activator of CGL expression ([@bib49]). Future experiments are required to determine the importance of these mechanisms to overall regulation of H~2~S production and the contribution of increased H~2~S to the individual and shared phenotypes associated with DR and reduced GH and/or TH signaling. Together, they represent potential targetable pathways toward harnessing endogenous H~2~S production for beneficial outcomes.

Inhibition of TH and GH Activity as a Novel Mechanism of H~2~S Action {#sec3.3}
---------------------------------------------------------------------

Reduced insulin/IGF-1 signaling, often accompanied by reduced circulating levels of these hormones and increased sensitivity to their action, is a feature shared by multiple rodent models of extended longevity. Our finding that H~2~S is required in certain contexts for downregulation of IGF-1 production suggests control of IGF-1 as a novel mechanism by which H~2~S can exert its pleiotropic effects on health and longevity.

By what mechanism could H~2~S control hepatic IGF-1 production? The observation that CGL was required for lowering circulating levels of T~4~ and IGF-1 in two different models of hypothyroidism, combined with the ability of TH to activate GHR/IGF-1 gene expression ([@bib37], [@bib65]), suggests that the compromised ability to reduce circulating T~4~ may be partially responsible. Consistent with the potential of H~2~S to affect TH, H~2~S donors present in garlic suppress TH signaling in rats ([@bib64]), and addition of NaHS blocks the production and/or secretion of GH from pituitary-derived cells ([@bib50]). Similarly, we found that increased CGL expression and/or exogenous H~2~S addition were sufficient to decrease circulating TH and IGF-1 in vivo ([Figures 7](#fig7){ref-type="fig"} and [S7](#mmc1){ref-type="supplementary-material"}).

Finally, we note that while a reduction in circulating IGF-1, which is produced mainly by liver, correlates with extended longevity, hepatic IGF-1 expression (and hence circulating IGF-1) can be reduced without longevity benefits, as in liver-specific IGF-1KO mice ([@bib69]). Future studies are required to determine the relative importance of hepatic H~2~S production on lifespan, as well as the effects of TH/GH signaling on H~2~S production in other tissue types.

Implications for Human Health {#sec3.4}
-----------------------------

While GH and TH signaling both decrease with age, it remains unclear if these changes are adaptive or maladaptive, and if preventing this decline alters healthy aging. GH supplementation results in increased lean body mass, decreased fat mass, and gains in muscle strength. However, it is also associated with edema, carpal tunnel syndrome, joint pain, and an increase in type 2 diabetes and glucose intolerance ([@bib44]). Increased TH results in DNA damage and premature senescence in vitro and in vivo ([@bib74]). Here we show that GH and TH supplementation suppresses H~2~S production. Because H~2~S is positively correlated with improved stress resistance and health, our findings raise concerns about the use of GH and/or TH supplementation as anti-aging or performance-enhancing therapies.

Conclusions {#sec3.5}
-----------

Previously we found that increased endogenous H~2~S production is in part responsible for the pleiotropic effects of DR. Here we found that TH and GH, two endocrine hormones associated with longevity control, are regulators of hepatic H~2~S production. TH and GH independently and additively suppressed H~2~S production through inhibition of CGL gene expression and control of substrate availability via autophagy, respectively. Unexpectedly, CGL-dependent H~2~S itself was required for feedback regulation of TH signaling via negative regulation of T~4~ levels and GH signaling through negative regulation of IGF-1. Together, these data point to H~2~S as a potential downstream mediator of benefits shared between decreased GH/TH signaling and DR.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Anti-CGL (Anti-Cystathionase)AbcamAb151769Anti-CBSAbcamAb135626Anti-3MST (Anti-MPST)SigmaHPA001240Anti-Stat5Santa CruzSc-835Anti-p-Stat5Cell Signaling Technology9359Anti-GNMTAvivaARP43565_P050Anti-AHCYAbcamAb56146Anti-ATF4 (Anti-CREB-2)Santa CruzSc-200Anti ATG5NovusNB110-53818Anti ATG7SigmaA2856Anti-beta TubulinCell Signaling2128Anti-ActinCell Signaling4970HRP conjugated anti-rabbitDakoP044801-2**Bacterial and Virus Strains**Ad-CMV-CGL (Ad-mCTH)Vector BiolabsADV-256305Ad-CMV-NullVector Biolabs1300Lentiviral sh-GFPLaboratory of Dr. Alec KimmelmanN/ALentiviral sh-ATG5Laboratory of Dr. Alec KimmelmanN/ALentiviral sh-ATG7Laboratory of Dr. Alec KimmelmanN/A**Biological Samples**Livers (frozen) taken from experimental mouse strains listed in the Experimental Models: Organisms/Strains sectionSee Experimental Models: Organisms/Strains sectionSee Experimental Models: Organisms/Strains sectionSerum/Plasma (frozen) taken from experimental mouse strains listed in the Experimental Models: Organisms/Strains sectionSee Experimental Models: Organisms/Strains sectionSee Experimental Models: Organisms/Strains section**Chemicals, Peptides, and Recombinant Proteins**NaHSSigma161527GYY4137SigmaSML0100LanreotideSigmaSML0132PTU/LID dietHarlan TekladTD 95125T3 (Triiodo-L---thyronine)SigmaT2752GC-1Laboratory of Dr. Thomas Scanlan[@bib14]GH (growth hormone)SigmaS8648FGF21GenscriptZ03290BafilomycinSigmaB1793ChloroquineSigmaC6628DL-PropargylglycineSigmaP7888Aminooxyacetic acidSigmaC13408AZD1480SelleckchemS2162Passive Lysis Buffer (5x)PromegaE1941PLP (Pyridoxal 5′-phosphate)SigmaP9255L-cysteineSigmaC7352lead (II) acetate trihydrateSigma316512P3 H2S Detection ProbeFrom the lab of Prof. K.H. Ahn[@bib62]**Critical Commercial Assays**Mouse/Rat IGF-1 ELISA kitR&D SystemsSMG100T4 ELISA kitDiagnostic Automation/ Cortez Diagnostics, Inc3149-18MILLIPLEX MAP Mouse Endocrine (TSH) AssayEMD MilliporeMPTMAG-49K**Experimental Models: Cell Lines**Hepa1-6 2Cl BirA/TRbetaLaboratory of Dr. Anthony N. HollenbergN/AHepa1-6 (mouse liver hepatoma)ATCCCRL-1830Primary mouse hepatocytes prepared from C57BL/6 mice (freshly isolated in the lab of Dr. James Mitchell for each experiment)Jackson Laboratories and laboratory of Dr. James R. Mitchell000664 and this paperATG5 Knockout mouse embryonic fibroblastsFrom the laboratory of Dr. Gokhan Hotamisligil[@bib72]ATG7 Knockout mouse embryonic fibroblastsFrom the laboratory of Dr. Gokhan Hotamisligil[@bib72]Primary CGL WT and KO mouse tail dermal fibroblastsFrom the laboratory of Dr. James R. MitchellThis paper**Experimental Models: Organisms/Strains**129/C57BL/6 background WT and KO CGL Male and Female MiceLaboratories of Dr. Rui Wang and Dr. James R. Mitchell[@bib31], [@bib71]WT and LirKO Female MiceLaboratory of Dr. James R. Mitchell[@bib29]Male and Female WT and Snell Dwarf miceLaboratory of Dr. Richard Miller[@bib20]Female WT and Ames Dwarf miceLaboratory of Dr. Andrzej Bartke[@bib53]Male and Female WT and GHRKO MiceLaboratory of Dr. Richard Miller[@bib68]Male and Female WT and IRS-1 KO miceLaboratory of Dr. Colin Selman[@bib58]Male WT and FGF21 overexpressing miceLaboratory of Dr. Pavlos Pissios[@bib35]TRbeta NI/NI, NI/PV, and mutant PV/PV miceLaboratory of Dr. Sheu-yann Cheng([@bib34]C57BL/6 miceJackson Laboratories000664B6D2F1 hybrid miceJackson Laboratories100006**Oligonucleotides**IGF-1 F: TGCTTGCTCACCTTCACCA IGF-1 R: CAACACTCATCCACAATGCCN/AN/AGHR F: ATTCACCAAGTGTCGTTCCC GHR R: TCCATTCCTGGGTCCATTCAN/AN/ACGL F: TTGGATCGAAACACCCACAAA CGL R: AGCCGACTATTGAGGTCATCAN/AN/ACBS F: GGGACAAGGATCGAGTCTGGA CBS R: AGCACTGTGTGATAATGTGGGN/AN/AHPRT F:TTTCCCTGGTTAAGCAGTACAGCCC HPRT R:TGGCCTGTATCCAACACTTCGAGAN/AN/ARPL13 F:TTCGGCTGAAGCCTACCAGAAAGT RPL13 R:TCTTCCGATAGTGCATCTTGGCCTN/AN/AMAT1A F: GATAGCAGATCTGAGGCGCT MAT1A R: TGCACCATTATCCTGCATGTN/AN/AGNMT F: AAGAGGGCTTCAGCGTGATG GNMT R: CTGGCAAGTGAGCAAAACTGTN/AN/AAHCY F: CGCCAGCATGTCTGATAAAC AHCY R: CCTGGCATCTCATTCTCAGCN/AN/ABHMT F: TTAGAACGCTTAAATGCCGGAG BHMT R: GATGAAGCTGACGAACTGCCTN/AN/A*For a full list of all primers used, please see*[Table S1](#mmc1){ref-type="supplementary-material"}**Software and Algorithms**ImageJNational Institutes of HealthWindows version,\
<https://imagej.nih.gov/ij/download.html>

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, James R. Mitchell (<jmitchel@hsph.harvard.edu>).

Experimental Models {#sec4.3}
-------------------

### In Vivo Animal Studies {#sec4.3.1}

All experiments were performed with the approval of the Institutional Animal Care and Use Committee (IACUC) from the respective institutions. Except where indicated in this paper or cited in the respective references, animals were bred and maintained under standard housing conditions with *ad libitum* access to food (Purina 5058) and water, 12-hour light/12-hour dark cycles, temperature between 20--23°C with 30%--70% relative humidity, and weaned from their mothers between 3-4 weeks of age. Mice used included: young adult (10-15 week old) male and (1-year old) female CGLKO and WT control mice on a mixed 129/C57BL/6 background ([@bib31], [@bib71]); female (10-16 week old) LIrKO and control mice generated by crossing *Ir*^*fl/fl*^ (WT) mice with *Ir*^*fl/fl*^*\|Albumin-Cre*^*+/−*^ (LIrKO) mice as previously described ([@bib29]); male and female Snell Dwarf and WT littermates aged 4-5 months ([@bib20]); 18-month female Ames Dwarf and WT littermates treated daily with recombinant growth hormone during a 6-week period early in life (weeks 2-8) as described ([@bib53]), male and female GHRKO and WT littermates aged 7-8 months ([@bib68]), sixteen week old male and female IRS-1 KO and WT littermates ([@bib58]); male FGF21 overexpressing (OE) transgenic and WT littermates ([@bib35]) and TRβ WT (NI/NI), heterozygote (NI/PV) and Mutant (PV/PV) mice as previously described ([@bib34]).

Lanreotide (Sigma) was administered to 10 week old male WT B6D2F1 hybrids (Jackson Labs) via daily sub-cutaneous injection at 0.4 mg/kg ([@bib22]) in sterile saline once/day for 7 days prior to euthanasia and organ harvest. CGL was overexpressed by IV injection of 10^10^ PFUs of Ad-CMV-CGL (ADV-256305) or control Ad-CMV-Null virus (Vector Biolabs) into 10 week old male WT B6D2F1 hybrids as previously described ([@bib31]) 7 days prior to blood serum collection for IGF-1 determination. Hydrogen sulfide supplementation was performed in male C57BL/6 mice (Jackson) using NaHS (Sigma) (1mM) and GYY4137 (Sigma) (260μM) in the drinking water starting at 10 weeks of age for 2 weeks, with supplementation of additional NaHS every two days and GYY4137 after the first week and with blood taken for analysis on day 0, 7, and 14. Young adult (10 to 15 weeks of age) male CGL WT and KO mice were fasted of food for three days with *ad libitum* access to drinking water and blood/serum sampled at Day 0 and Day 3. 1-year old female CGL WT and KO mice were fasted of food for two-days and given *ad libitum* access to drinking water, and then blood taken on Day 0 and Day 2, with one of the two CGL KO groups receiving NaHS injection in sterile saline at a dose of 5mg/kg per injection after the first blood draw on day 0, day 1, and just prior to harvest on day 2. 10-week old male B6D2F1 hybrids were kept on an *ad libitum* rodent diet and injected with NaHS in sterile saline at 5mg/kg and blood/serum taken 24-hours later for analysis. Recombinant human IGF-1 (rhIGF-1) at 500 μg/kg/d or recombinant human growth hormone (rhGH) at 2 mg kg/day (BID) were administered by intraperitoneal injection for 20 days in 12-week-old male C57BL/6 mice as described ([@bib41]). Modulation of thyroid hormone levels on a hypothyroid background was accomplished in 9-week old male C57BL6 mice maintained for 3 weeks on a PTU/LID diet (Harlan Teklad formula \# TD 95125) to induce hypothyroidism followed by saline or T3 (Sigma, St. Louis, MO) intraperitoneal injection once a day for 4 days to create hypothyroid (saline), euthyroid (0.5 μg/100g bodyweight of T3) or hyperthyroid (25 μg/100g bodyweight of T3) mice. For modulation of thyroid hormone levels on a euthyroid background, 10 week old male mice fed a standard rodent diet (Labdiet Chow) were injected intraperitoneally with saline or 25 μg/100g bodyweight of T3 once a day for 4 days. GC-1 ([@bib14]) was administered to 10-week old male C57BL6 mice fed a standard rodent diet (Labdiet Chow) by intraperitoneal injection (3 μg/100g bodyweight) once a day for 4 days.

### Cell Lines and In Vitro Tissue Culture Studies {#sec4.3.2}

Mouse primary hepatocytes from 8-10 week old female WT C57BL/6 mice (Jackson Laboratories) were isolated via portal vein collagenase treatment (Liberase, Roche) followed by Percoll gradient centrifugation and culturing in William's E media with 5% FBS at 37°C, 20% O~2~ and 5% CO~2~. The Hepa1-6 cell line, originally obtained from a C57L mouse (sex unknown), was maintained in DMEM media with 10% FBS. Hepa1-6 2Cl BirA/TRβ cells, which were generated by sequentially transfecting BirA And TRβ into Hepa 1-6 cells and selecting clones using geneticin and puromycin, were maintained in DMEM+Glutamax with 10% vol/vol FBS supplemented with Gibco Antibiotic-Antimycotic, Geneticin, and Puromycin at 37°C, 20% O~2~ and 5% CO~2~. Lentiviral infections of Hepa1-6 cells with sh-GFP, sh-ATG5 or sh-ATG7 were performed in the presence of 10% FBS and 8μg/ml Polybrene on two consecutive days; infected Hepa1-6 cells were selected with 3μg/ml puromycin for 2 weeks before use and maintained with 3μg/ml puromycin. Genetically deficient ATG5 fibroblasts originally from 129/C57BL mixed background embryos (sex unknown) and ATG7 fibroblasts originally from C57BL/6 embryos (sex unknown) were a gift from the lab of Dr. Gokhan Hotamisligil and previously reported ([@bib72]). CGL WT and KO mouse dermal fibroblasts from tail skin were prepared from female CGL WT and KO mice and maintained in 20% FBS in DMEM +Penicillin/Streptomycin. For differential H~2~S determination, an equal number of cells were seeded onto 12-well plates and incubated overnight in media +/- serum with or without the following drugs/hormones: GH (0.1-1μg/mL, Sigma), FGF21 (100nM, Genscript), T3 (10&100nM, Sigma), Bafilomycin (1μM, Sigma), Chloroquine (10μM, Sigma), DL-Propargylglycine (PAG) (100μM, Sigma), Aminooxyacetic acid (AOAA) (100μM, Sigma), AZD1480 (10μM, Selleckchem).

Method Details {#sec4.4}
--------------

### Lead Sulfide Method for Determination of H~2~S Production Capacity {#sec4.4.1}

H~2~S production capacity in liver homogenates was measured as previously described ([@bib31]). Briefly, fresh or flash frozen liver was homogenized in passive lysis buffer (Promega) and volume normalized to protein content. An equal volume/protein amount was added to a reaction master mix containing PBS, 1mM Pyridoxal 5′-phosphate (PLP) (Sigma) and 10mM Cys (Sigma) and placed in a well-format (12-well to 96-well) plate. H~2~S detection paper, saturated with lead acetate and then dried, was placed above the plate and incubated 1-2hrs at 37°C until H~2~S in the gas phase reacted with the paper to form dark lead sulfide. In live primary hepatocytes, growth media was supplemented with 10mM Cys and 10μM PLP, and a lead acetate H~2~S detection paper placed over the plate for 2-24hrs at 37°C in a CO~2~ incubator.

### H~2~S Detection with Fluorescent Probe {#sec4.4.2}

#### Cultured Cells {#sec4.4.2.1}

The chemical H~2~S probe P3 ([@bib62]) was added at 10μM final concentration directly to the cell culture media following overnight treatment of cells (e.g. +/- serum, +/- hormones/drugs). One hour after P3 addition, H~2~S-activated P3 fluorescence was quantitated on a BioTek plate reader (excitation 360nm, emission 528nm). Alternately, cells were washed 1x with PBS, fixed in ice-cold methanol for 10 minutes, dried, and stored at -20°C until imaging via 2-photon microscopy (Mai Tai, Spectra-Physics) with excitation at 880 nm and emission 520-530nm using a 10x objective following rehydration in 1x PBS. Images were analyzed using the Integrated Density (IntDen) function of ImageJ software to determine the total florescence of the entire image.

#### Liver *Ex Vivo* Analysis {#sec4.4.2.2}

Flash frozen liver from adult male WT or Snell Dwarf mice was embedded in OCT media and cryosectioned onto glass slides, thawed to room temp and incubated in PBS containing 10μM P3 at room temperature for 30 minutes prior to fixation and then subsequent imaging via 2-photon microscopy using a 60x objective. The fluorescence signal was determined using the Integrated Density (IntDen) function of ImageJ obtained from analyzing the entire image and averaging three images per animal and three animals/group. These values were then normalized to the average wildtype control value (set to 1).

### PTU/LID Diet for Altering Thyroid State {#sec4.4.3}

10-15 week old WT or CGLKO male mice were given *ad libitum* access to the Normal control 5058 diet (Purina), or the low iodine diet with 0.15% PTU; PTU/LID (Harlan Teklad) for three weeks prior to assay or harvest.

### Western Blots/Protein Analysis {#sec4.4.4}

Protein analysis was performed via western blot on tissue and cell homogenates in passive lysis buffer (Promega), separated by SDS-PAGE, transferred to PVDF membrane (Whatman) and blotted for CGL (ab151769 Abcam), CBS (ab135626 Abcam), 3MST (HPA001240 Sigma), Stat5 (sc-835 Santa Cruz), p-Stat5 (\#9359 Cell Signaling Technology), GNMT (Aviva), AHCY (Abcam ab56146), ATF4 (aka CREB-2 C-20, Santa Cruz Biotechnology sc-200), ATG5 (Novus, NB110-53818), ATG7 (Sigma, A2856), β-Tubulin 9F3 (\#2128 Cell Signaling) or Actin (\#4970 Cell Signaling) followed by HRP conjugated secondary anti-rabbit antibody (Dako).

### qPCR/mRNA Analysis {#sec4.4.5}

Total RNA was isolated from tissues and cells using standard phenol-chloroform/isopropanol extraction and cDNA synthesized by random hexamer priming with the Verso cDNA kit (Thermo). qRT-PCR was performed with SYBR green dye (Lonza) and TaqPro DNA polymerase (Denville) or Taqman Universal PCR Master Mix (Thermo Fisher Scientific). Fold changes were calculated by the ΔΔC~t~ method using the genes Hprt and/or Rpl13 as controls and ultimately normalized to the control for each respective experiment, or normalized to a standard curve utilizing cyclophilin as an internal control. Primer sets used for PCR are listed in the [Key Resources Table](#sec4.1){ref-type="sec"} and in [Table S1](#mmc1){ref-type="supplementary-material"}.

### ChIP of TRβ {#sec4.4.6}

TRβ1-binding sites in gnmt, cth, cbs, mat1a and bhmt were identified in a previous study that characterized the cistrome of TRβ1 in mouse liver ([@bib56]). ChIP-qPCR was performed as previously described. Briefly, hypothyroid mice that expressed BirA ubiquitously were transduced with an adenovirus expressing wither GFP alone or Blrp-TRβ1 and GFP together. Subsequently half the hypothyroid mice in each group were given T3 injections to render them hyperthyroid. Livers from these mice were collected for chromatin affinity precipitation using streptavidin-agarose beads and qPCR was performed using primer sequences directed against genomic sites identified by ChIP-seq analysis.

### Liver Metabolomics {#sec4.4.7}

*Ex vivo* mouse liver polar metabolomics was performed using targeted tandem mass spectrometry (LC-MS/MS) with polarity switching and selected reaction monitoring (SRM) with a AB/SCIEX 5500 QTRAP Mass spectrometer as previously described in ([@bib73]).

### Detection of Serum Hormones: IGF-1, T4, TSH {#sec4.4.8}

Serum IGF-1 was detected using the IGF-1 Mouse/Rat ELISA kit (R&D Systems) following the manufacturer's recommendations. Total plasma T4 levels were measured using a commercially available ELISA Kit (Diagnostic Automation/ Cortez Diagnostics, Inc Calabasas, CA). Thyroid-stimulating hormone (TSH) was measured in plasma via Milliplex MAP (mutianalyte panels) (mouse thyroid hormone TSH panel; EMD Millipore, Billerica, MA).

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

Data are displayed as means +/- standard error of the mean (SEM) and statistical significance assessed in GraphPad Prism and/or Microsoft Excel using Student's t tests to compare values between two specific groups, and one-way or two-way ANOVA followed by Tukey's or Sidak's Multiple Comparisons Tests when comparing more than two groups/variables at a given time. A P-value of 0.05 or less was deemed statistically significant in all of these statistical tests. Statistical details and results of experiments are found in the figures and figure legends. Quantification of western blot images, lead sulfide H~2~S production capacity assays, and 2-photon H~2~S production images was done using the IntDen measurement in ImageJ software and normalized to the respective control group in each experiment when applicable. All experiments examining hepatic H~2~S production were initially performed in a blinded fashion and technical repeats were done at least twice. Snell Dwarf and GHRKO experiments were repeated twice independently for a total of 6/genotype per sex or 12 total/genotype, and PTU/LID diet experiments in CGL WT and KO mice were repeated independently three times for a total of 11-12 animals/group.
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